Omniver eso dicen pero no se donde se sacan los billetes para volar hacia Atlanta yá
------
ZGNX
Supongo que esta FDA news podria hacer "pupa" a Zohydro, pero revisado en detalle veo que es para dolor agudo y el Zo para dolor cronico pero si este es lo que tanto amenazaba Purdue con sacar al mercado que fue lo que inicio la t.bajista de ZGNX, pues no se ajusta a lo que decia S.Alpha- porque ...Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection. When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less liked by abusers than oxycodone alone. Naloxone is a medication that is commonly used to reverse the effects of opioid overdose. Targiniq ER can still be abused, including when taken orally (by mouth), which is currently the most common way oxycodone is abused. It is important to note that taking too much Targiniq ER for purposes of abuse or by accident, can cause an overdose that can result in death.
Es decir lo que con tanto bombo y platillo anuncio Purdue no es lo que se acaba de aprobar por la FDA
--
Targiniq ER is manufactured by Stamford-based Purdue Pharma L.P.
Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product’s abuse-deterrent properties consistentwith the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406407.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery